PDCD1 and hepatocellular carcinoma: In HCC patients receiving a combination of PD-1 inhibitors, angiogenesis inhibitors, and concurrent first-line antivirals, 16 out of 218 patients (7.3 %) experienced HBV reactivation (Wang et al., 2024).